跳至主要内容
临床试验/NCT05365230
NCT05365230
已完成
4 期

A Randomized Trial Evaluating Personalized vs Guideline-based Well Follow-up Strategies for Patients With Early-stage Breast Cancer (REaCT-Wellness)

Ottawa Hospital Research Institute2 个研究点 分布在 1 个国家目标入组 261 人2022年8月19日

概览

阶段
4 期
干预措施
On-demand personalized follow-up care
疾病 / 适应症
Breast Cancer
发起方
Ottawa Hospital Research Institute
入组人数
261
试验地点
2
主要终点
Health-Related Quality of Life
状态
已完成
最后更新
25天前

概览

简要总结

After breast cancer patients complete the acute phase of their treatment (i.e. surgery, chemotherapy and/or radiation therapy), they are routinely followed in clinic every 3-6 months for several years. Multiple guideline recommendations exist with no consensus on the optimal follow-up schedule due to lack of randomized data to support any particular follow-up recommendation. Therefore the investigators propose a randomized trial evaluating personalized vs guideline-based well follow-up strategies for patients with early-stage breast cancer.

详细描述

After breast cancer patients complete the acute phase of their treatment (i.e. surgery, chemotherapy and/or radiation therapy), they are routinely followed in clinic every 3-6 months for several years. Multiple guideline recommendations exist with no consensus on the optimal follow-up schedule due to lack of randomized data to support any particular follow-up recommendation. The frequency of follow-up varies between and within different institutions. To date, no de-escalation strategy has appropriately evaluated patient reported outcomes such as quality of life or perception of care. There has been a growing body of evidence that de-intensification of follow-up is safe, effective and reduces costs for both patients and the health care system. Therefore the investigators propose a randomized trial evaluating personalized vs guideline-based well follow-up strategies for patients with early-stage breast cancer.

注册库
clinicaltrials.gov
开始日期
2022年8月19日
结束日期
2025年8月15日
最后更新
25天前
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

责任方
Sponsor

入排标准

入选标准

  • Being referred to the Wellness Beyond Cancer Program (WBCP) for routine follow-up after completion of acute phase of treatment for invasive breast cancer

排除标准

  • History of prior invasive breast cancer, recurrent brest cancer or metastatic breast cancer
  • Currently receiving zoledronate, LHRH (Gonadotropin-releasing hormone) or abemaciclib

研究组 & 干预措施

On-demand personalized follow-up care

On-demand personalized follow-up care (on-demand access to a Wellness Beyond Cancer Program (WBCP) nurse and an annual follow-up by telephone with WBCP nurse following the patient's annual mammogram). Both groups of participants will have yearly mammograms (current standard of care) organized by their healthcare provider.

干预措施: On-demand personalized follow-up care

Guideline-based follow-up care

Guideline-based follow-up care (i.e. current standard of care). Both groups will have yearly mammograms (current standard of care) organized by their healthcare provider.

干预措施: Guideline-based follow-up care (standard of care)

结局指标

主要结局

Health-Related Quality of Life

时间窗: 24 months after randomization

Health-Related Quality of Life as determined by the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaire. The FACT-G is a 27-item questionnaire designed to measure four domains of Health related quality of life (HRQOL) in cancer patients: physical, social, emotional and functional well-being.

次要结局

  • Fear of recurrence(24 months after randomization)
  • Anxiety levels(24 months after randomization)
  • Treatment related toxicity concerns(24 months after randomization)
  • Recurrence-free survival(24 months after randomization)
  • Cost-effectiveness(24 months after randomization)
  • Patient visits(24 months after randomization)

研究点 (2)

Loading locations...

相似试验